Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GOT1 | P17174 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1189244 | 0.85 | JUN (0.33) | — | |
| SCHEMBL24238696 | 0.75 | TDP1 (0.40) | TDP1 | |
| SCHEMBL1188150 | 0.74 | TDP1 (0.43) | ALDH1A1TDP1 | |
| SCHEMBL29919389 | 0.74 | TDP1 (0.43) | ALDH1A1TDP1 | |
| SCHEMBL21745681 | 0.71 | PSMB5 (0.33) | TDP1 | |
| SCHEMBL8140709 | 0.70 | ALDH1A1 (0.40) | ALDH1A1MAPTGAATDP1 | |
| SCHEMBL10622724 | 0.70 | TDP1 (0.54) | ALDH1A1MAPTGAAGOT1TDP1 | |
| SCHEMBL31021534 | 0.70 | CHEK1 (0.42) | — | |
| SCHEMBL1188706 | 0.68 | ALDH1A1 (0.39) | ALDH1A1MAPTGAAGOT1TDP1 | |
| SCHEMBL1189247 | 0.67 | JUN (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142551-B1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2142551-B1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| EP-2142551-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008130951-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130951-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD17B1, HSD11B1, HSD3B1 | ALDH1A1 51/4885MAPT 3803/4885GAA 557/4885 |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ALDH1A1 1015/4885MAPT 4600/4885GAA 3876/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ALDH1A1 2229/4885MAPT 4285/4885GAA 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.